JAK1 and type 1 diabetes mellitus: In humans, the JAK1/2 inhibitor Baricitinib was successful in slowing progression of T1D in a Phase 2 trial [BANDIT (74)], this research is being continued in the recently launched JAKPOT T1D study (NCT05743244) and T1DPlus (ISRCTN45965456).